Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus
| Autor: | Aurélien Amiot, Guillaume Bouguen, Guillaume Bonnaud, Yoram Bouhnik, Hervé Hagege, Laurent Peyrin-Biroulet, Vered Abitbol, Georgia Malamut, Aurelien Amiot, Arnaud Boruchowicz, Laurent Siproudhis, Marie DeWitte, Carmen Stefanescu, Anthony Buisson, Ludovic Caillo, Maryan Cavicchi, Nina Dib, Isabelle Etienney, Jerome Filippi, Mathurin Fumery, Felix Goutorbe, Laurent Costes, Mathias Vidon, Frédéric Heluwaert, Christophe Locher, Mehdi Kaassis, Patrick Mamou, Chloe MARTINEAU, Nicolas Mathieu, Benjamin Pariente, Pauline WILS, Stephane Nancey, Magalie Picon-Coste, Camille Zallot, Marie-Pierre Pingannaud, Xavier Roblin, Julia Roux, Melanie Serrero, Marion Simon, Florence Skinazi, Lucas Spindler, Stephanie Viennot |
|---|---|
| Přispěvatelé: | Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Ambroise Paré [AP-HP], Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHI Créteil, Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Jonchère, Laurent, Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Clinical guidelines
Crohn’s disease medicine.medical_specialty Consensus [SDV]Life Sciences [q-bio] Antibodies Monoclonal Humanized Inflammatory bowel disease Severity of Illness Index Vedolizumab 03 medical and health sciences 0302 clinical medicine Maintenance therapy Crohn Disease Gastrointestinal Agents Ustekinumab medicine Humans Intensive care medicine Reimbursement Crohn's disease Tofacitinib Hepatology business.industry Gastroenterology medicine.disease Ulcerative colitis 3. Good health Algorithm [SDV] Life Sciences [q-bio] 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Colitis Ulcerative Tumor Necrosis Factor Inhibitors France business Immunosuppressive Agents medicine.drug |
| Zdroj: | Digestive and Liver Disease Digestive and Liver Disease, 2021, 53 (1), pp.35-43. ⟨10.1016/j.dld.2020.10.018⟩ Digestive and Liver Disease, WB Saunders, 2021, 53 (1), pp.35-43. ⟨10.1016/j.dld.2020.10.018⟩ Digestive and Liver Disease, Elsevier, 2021, 53 (1), pp.35-43. ⟨10.1016/j.dld.2020.10.018⟩ |
| ISSN: | 1590-8658 |
| DOI: | 10.1016/j.dld.2020.10.018⟩ |
| Popis: | International audience; BACKGROUND: New treatments and therapeutic approaches repeatedly emerged in the field of inflammatory bowel disease. AIM: to update the French treatment algorithms for Crohn’s disease (CD) and ulcerative colitis (UC). METHODS: A formal consensus method was used to determine changes to the treatment algorithms for various situations of CD and UC. Thirty-seven experts voted on questions that had been drafted by the steering committee ahead of time. Consensus was defined as at least 66% of experts agreeing on a response. RESULTS: Anti-TNF were reinforced as a first-line therapy rather than the use of immunosuppressant alone. Vedolizumab for UC, ustekinumab for CD took place as second-line maintenance therapy and potentially as a first-line therapy in the setting of unrestricted reimbursement for vedolizumab. Tofacitinib was recommended by the experts in case of vedolizumab failure for UC. Algorithms for complicated CD with abscess, intestinal and complex anal fistula were updated according to recent prospective cohort studies. CONCLUSION: The changes incorporated to the algorithms provide up-to-date and easy-to-use guidelines to treat patients with IBD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect